Atrovent HFAipratropium

34,822 adverse event reports submitted to the FDA (1996–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Atrovent HFA in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Atrovent HFA adverse event reports by reporter sex
SexReports
Female18,645
Male13,725
Unknown111

By Age Group

View age group data as a table
Atrovent HFA adverse event reports by reporter age group
Age groupReports
0-171,155
18-341,043
35-492,302
50-646,355
65-745,771
75+6,841

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Atrovent HFA. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Atrovent HFA adverse event reports by reported outcome
OutcomeReports
Hospitalization15,437
Other Serious15,429
Non-Serious8,103
Death4,624
Life-Threatening2,225
Disability1,054

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Atrovent HFA. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Atrovent HFA adverse event reports by year
YearReports
19961
19991
20032
2004946
20051,234
2006912
2007804
2008979
20091,005
20101,010
20111,198
20121,180
20131,068
20141,183
20151,440
20161,832
20171,624
20182,101
20192,338
20202,744
20212,664
20222,005
20231,811
20242,132
20252,089
2026 (partial)519

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Atrovent HFA

In FDA adverse event reports that mention Atrovent HFA, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026